Disc Medicine, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IRON | AGIO | COAG | INCY | LGND | RLAY | |
|---|---|---|---|---|---|---|
| Market cap | 3.70B | 1.87B | 2.11B | 25.04B | 6.32B | 3.95B |
| P/E (TTM) | — | — | — | 62.7 | 127.0 | — |
| Forward P/E | -12.2 | -7.8 | -17.7 | 14.2 | 25.9 | -11.0 |
| Price/book | 5.0 | 1.8 | 4.6 | 4.4 | 6.6 | 5.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −8.10% | −22.15% | +26.76% | +16.78% | +51.82% | +176.11% |
| Today | +2.61% | +0.58% | +4.62% | +4.47% | +0.83% | +3.38% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IRON news ›Dime Commercial Bancshares: $15.6K proposed sale
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease ReconAfrica Announces Grant of Stock Options to New Director Palantir…
The Degenerative Disc Disease Treatment Market is Projected to Reach $39.89 Billion by 2030
openPR.com The Degenerative Disc Disease Treatment Market is Projected to Reach $39.89 Billion by 2030 Press release from: The Business Research Company Permanent link to this press release: You can edit o
Experimental EPP therapy increases pain-free time in light in trial
Phase 3 study met all main and secondary goals, with significant PPIX reductions Written by Patricia Inácio, PhD | Oct. 28, 2026 Disc Medicine’s experimental oral therapy bitopertin significantly reduced levels of protoporphyrin IX (PPIX),…
Ryder System director proposes $463K share sale
SEGG Media Reports More Than 1,500% Year-Over-Year Revenue Growth in Second Quarter, Driven by Veloce uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the…
Vivex Biologics' VIA Disc® NP Meets Primary Endpoint in Pivotal, Sham-Controlled ASCEND Trial Published in Journal of Clinical Medicine
The first intradiscal allograft to succeed in a rigorous, sham-controlled trial for chronic lumbar discogenic pain, a leading driver of the world’s #1 cause of disability Rey Pascual, Vivex’s Co-President, added, “The strength of a…
Disc Medicine (NASDAQ:IRON) Director Sells $424,694.40 in Stock
Posted by Danessa Lincoln on Oct 24th, 2026 Kevin Bitterman also recently made the following trade(s): Disc Medicine (NASDAQ:IRON – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported…
Disc Medicine Raises $450 Million in Public Offering to Extend Cash Runway Into 2030
TradingView Disc Medicine Raises $450 Million in Public Offering to Extend Cash Runway Into 2030 Disc Medicine entered into an underwriting agreement for a public offering of 6 million common shares at $75 per shar
Disc Medicine sets $75 share price for $450M offering
Disc Medicine (IRON) priced an upsized public offering of 6M common shares at $75 each, with gross proceeds expected to reach $450M - Disc Medicine (IRON) priced an upsized public offering of 6M common shares at $75 each, with gross…
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
The Daily Tribune News WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commerci
Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP - Slideshow
2026-10-21. The following slide deck was published by Disc Medicine, Inc. The following slide deck was published by Disc Medicine, Inc. in conjunction with this event.
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net24
- marketscreener.com7
- seekingalpha.com5
- prnewswire.com4
- globenewswire.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 65 articles, not a forecast.